SCHEMBL11943958

SCHEMBL11943958

CCOCCOc1c(N2CCN(S(=O)(=O)C(C)C)CC2)cnn(-c2ccccc2F)c1=O

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 2/20 0.43
▸ LMNA P02545 3/20 0.42
▸ GAA P10253 2/20 0.42
▸ HTT P42858 1/20 0.42
▸ SCN9A Q15858 3/20 0.41
▸ KDM4E B2RXH2 2/20 0.40
▸ GLA P06280 1/20 0.40
▸ MAPK1 P28482 2/20 0.40
▸ TSHR P16473 2/20 0.40
▸ MAPT P10636 2/20 0.39
▸ ALDH1A1 P00352 4/20 0.39
▸ POLB P06746 2/20 0.39
▸ PKM P14618 1/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ TP53 P04637 2/20 0.39
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11945079 0.90 ALDH1A1 (0.51) HSD17B10LMNAGAAHTTSCN9A
SCHEMBL11943939 0.88 MAPT (0.52) LMNAGAAHTTMAPTALDH1A1
SCHEMBL11945080 0.88 KDM4E (0.57) HSD17B10LMNAGAAHTTSCN9A
SCHEMBL11943957 0.86 HSD17B10 (0.46) HSD17B10LMNAGAAHTTSCN9A
SCHEMBL11943955 0.86 POLB (0.45) LMNAGAAKDM4EMAPK1MAPT
SCHEMBL11943954 0.86 MEN1 (0.42) HSD17B10LMNAGAAKDM4EMAPT
SCHEMBL11945127 0.85 MAPT (0.38) HSD17B10LMNAGAAKDM4EMAPT
SCHEMBL17058153 0.83 SCN9A (0.40) HSD17B10LMNAGAAHTTSCN9A
SCHEMBL11943950 0.83 POLB (0.49) LMNAGAAKDM4EMAPTALDH1A1
SCHEMBL11943979 0.83 MAPT (0.42) LMNAMAPTALDH1A1POLBCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA HSD17B10 1101/4885LMNA 929/4885GAA 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback